Skip Navigation

Strengthen the Evidence for Maternal and Child Health Programs

Sign up for MCHalert eNewsletter

Search Results: MCHLine

Items in this list may be obtained from the sources cited. Contact information reflects the most current data about the source that has been provided to the MCH Digital Library.

Displaying records 1 through 5 (5 total).

Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. 2021. Aspirin use to prevent preeclampsia and related morbidity and mortality: Updated systematic review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality, 157 pp. (Evidence synthesis; no. 205; AHRQ publication; no. 21-05274-EF-1)

Annotation: This systematic review was conducted to support the United States Preventive Services Task Force in updating its 2014 recommendation on daily low dose aspirin use during pregnancy for individuals at increased risk for preeclampsia. The report reviewed updated evidence on the effectiveness and potential harms of daily aspirin use during pregnancy to prevent morbidity and mortality associated with preeclampsia. Data sources included MEDLINE, PubMed, Embase, and the Cochrane Collaboration Registry of Controlled Trials; results were limited to studies published between January 2013 and July 2019. The reviewed studies showed that daily aspirin use in pregnancy for individuals at increased risk for preeclampsia consistently led to beneficial effects on perinatal mortality, preterm birth, fetal growth restriction, and preeclampsia diagnosis.

Contact: U.S. Agency for Healthcare Research and Quality, 5600 Fishers Lane, Rockville, MD 20857, Telephone: (301) 427-1104 Secondary Telephone: (301) 427-1364 Web Site: http://www.ahrq.gov

Keywords: Pregnant women, Drugs, Evidence based medicine, High risk groups, Literature reviews, Maternal health, Perinatal care, Preeclampsia, Pregnancy, Pregnancy complications, Pregnancy outcomes, Preventive health services

U.S. Preventive Services Task Force. 2021. Aspirin use to prevent preeclampsia and related morbidity and mortality: Preventive medication--Final recommendation statement. Rockville, MD: U.S. Preventive Services Task Force, 6 pp.

Annotation: This report provides U.S. Preventive Services Task Force (USPSTF) recommendations for the use of aspirin to prevent preeclampsia in pregnant women. Information about other related issues is also offered. Topics include the importance of using low-dose aspirin to prevent preeclampsia, recognition of risk status, assessment of net benefit, practice considerations, an update of previous USPSTF recommendations, supporting evidence, research needs and gaps, and recommendations of others.

Contact: U.S. Preventive Services Task Force, 540 Gaither Road, Rockville, MD 20850, Telephone: (301) 427-1584 Web Site: http://www.uspreventiveservicestaskforce.org Available from the website.

Keywords: Aspirin, Guidelines, Preeclampsia, Pregnant women, Prevention

U.S. Preventive Services Task Force. 2017. Preeclampsia: Screening. Rockville, MD: U.S. Preventive Services Task Force,

Annotation: This resource presents the U.S. Preventive Services Task Force recommendation on screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy. The recommendation statement; supporting documents, including the research plan, evidence review, evidence summary, clinical summary; and related information for health professionals.

Contact: U.S. Preventive Services Task Force, 540 Gaither Road, Rockville, MD 20850, Telephone: (301) 427-1584 Web Site: http://www.uspreventiveservicestaskforce.org Available from the website.

Keywords: Childbirth, Evidence based medicine, Hospitals, Preeclampsia, Pregnancy induced hypertension, Pregnant women, Prenatal care, Reproductive health, Screening, Women', s health

California Maternal Quality Care Collaborative Preeclampsia Task Force. 2014. Preeclampsia toolkit: Improving health care response to preeclampsia–A California toolkit to transform maternity care. Stanford, CA: California Maternal Quality Care Collaborative, multiple items.

Annotation: This toolkit is designed to guide and support health professionals and others working in clinics, hospitals, and other health care settings develop methods within their facilities to recognize and respond to preeclampsia. Contents include care guidelines in checklist, flowchart, and table chart formats; a compendium of 18 best practice articles; a slide set for professional education; and educational material for pregnant women and their families.

Contact: California Maternal Quality Care Collaborative, Stanford University Medical School Office Building, 1265 Welch Road, MS 5415, Stanford, CA 94305, Telephone: (650) 725-6108 Fax: (650) 721-5751 E-mail: [email protected] Web Site: http://www.cmqcc.org Available from the website.

Keywords: Collaboration, Guidelines, Model programs, Perinatal care, Preeclampsia, Pregnant women, Program improvement, Quality assurance, Resources for professionals

U.S. Preventive Services Task Force. 2014. Low-dose aspirin for the prevention of morbidity and mortality from preeclampsia: Preventive medication. Rockville, MD: U.S. Preventive Services Task Force, multiple items.

Annotation: This resource provides a summary of recommendations and evidence on the use of low-dose aspirin as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. Additional contents include the rationale, and clinical and other considerations.

Contact: U.S. Preventive Services Task Force, 540 Gaither Road, Rockville, MD 20850, Telephone: (301) 427-1584 Web Site: http://www.uspreventiveservicestaskforce.org Available from the website.

Keywords: Drugs, Evidence based medicine, High risk groups, Preeclampsia, Pregnant women, Preventive health services, Treatment effectiveness evaluation
   

This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U02MC31613, MCH Advanced Education Policy, $3.5 M. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.